Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL56294 | 0.84 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2KDM4EKMT2AMEN1 | |
| SCHEMBL55895 | 0.75 | KMT2A (0.52) | ALDH1A1SMN1; SMN2KDM4EKMT2AMEN1 | |
| SCHEMBL9356593 | 0.73 | KDM4E (0.48) | ALDH1A1KDM4EKMT2AMEN1MAPT | |
| SCHEMBL11681383 | 0.72 | KDM4E (0.35) | ALDH1A1KDM4EKMT2AMEN1MAPT | |
| SCHEMBL9356896 | 0.71 | KDM4E (0.52) | ALDH1A1KDM4EKMT2AMEN1MAPT | |
| SCHEMBL14506039 | 0.70 | KDM4E (0.36) | ALDH1A1KDM4EKMT2AMEN1MAPT | |
| SCHEMBL5126540 | 0.69 | KDM4E (0.43) | SMN1; SMN2KDM4E | |
| SCHEMBL14506037 | 0.67 | KDM4E (0.44) | ALDH1A1KDM4EKMT2AMEN1MAPT | |
| SCHEMBL9898745 | 0.65 | KDM4E (0.30) | SMN1; SMN2KDM4E | |
| SCHEMBL11960017 | 0.64 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2KDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3133075-B1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-12-30 | — | — | EP | disclosed |
| US-9745325-B2 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-29 | — | — | US | disclosed |
| EP-3133075-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-02-22 | — | — | EP | disclosed |
| US-20170037057-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037057-A1 | FUSED HETEROCYCLIC COMPOUND | CDK8, CDK9, CDK19 | ALDH1A1 2989/4885SMN1; SMN2 3417/4885KDM4E 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.